Capital Research Global Investors’s AbbVie ABBV Stock Holding History

Capital Research Global Investors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.8B	Buy	31,254,786 +5,846,586	+23%	+$1.3B	1.05%	22
2025 Q4	$5.81B	Buy	25,408,200 +177,370	+0.7%	+$40.4M	1.07%	20
2025 Q3	$5.84B	Sell	25,230,830 -34,749	-0.1%	-$7.08M	1.1%	20
2025 Q2	$4.69B	Sell	25,265,579 -8,242,435	-25%	-$1.53B	0.94%	24
2025 Q1	$7.02B	Sell	33,508,014 -475,693	-1%	-$92.5M	1.53%	14
2024 Q4	$6.04B	Buy	33,983,707 +778,126	+2%	+$143M	1.24%	19
2024 Q3	$6.56B	Buy	33,205,581 +20,187	+0.1%	+$3.77M	1.36%	16
2024 Q2	$5.69B	Buy	33,185,394 +1,890,244	+6%	+$313M	1.25%	18
2024 Q1	$5.7B	Buy	31,295,150 +992,496	+3%	+$171M	1.29%	14
2023 Q4	$4.7B	Sell	30,302,654 -1,673,490	-5%	-$244M	1.16%	18
2023 Q3	$4.77B	Sell	31,976,144 -569,378	-2%	-$83.6M	1.31%	14
2023 Q2	$4.38B	Sell	32,545,522 -3,168,845	-9%	-$465M	1.18%	17
2023 Q1	$5.69B	Sell	35,714,367 -997,422	-3%	-$152M	1.62%	12
2022 Q4	$5.93B	Buy	36,711,789 +518,687	+1%	+$79.5M	1.79%	8
2022 Q3	$4.86B	Buy	36,193,102 +9,896,885	+38%	+$1.42B	1.6%	11
2022 Q2	$4.03B	Buy	26,296,217 +9,216,006	+54%	+$1.41B	1.25%	16
2022 Q1	$2.77B	Sell	17,080,211 -925,618	-5%	-$134M	0.68%	35
2021 Q4	$2.44B	Sell	18,005,829 -1,004,082	-5%	-$119M	0.54%	42
2021 Q3	$2.05B	Buy	19,009,911 +324,445	+2%	+$37.1M	0.48%	50
2021 Q2	$2.1B	Sell	18,685,466 -1,535,173	-8%	-$173M	0.49%	43
2021 Q1	$2.19B	Sell	20,220,639 -17,700,423	-47%	-$1.89B	0.54%	40
2020 Q4	$4.06B	Sell	37,921,062 -2,883,051	-7%	-$277M	1.05%	21
2020 Q3	$3.57B	Sell	40,804,113 -5,299,576	-11%	-$499M	1.07%	19
2020 Q2	$4.53B	Sell	46,103,689 -3,128,616	-6%	-$275M	1.43%	12
2020 Q1	$3.75B	Sell	49,232,305 -37,370,388	-43%	-$3.18B	1.47%	12
2019 Q4	$7.67B	Sell	86,602,693 -14,011,979	-14%	-$1.16B	2.3%	8
2019 Q3	$7.62B	Sell	100,614,672 -9,509,347	-9%	-$652M	2.5%	5
2019 Q2	$8.01B	Sell	110,124,019 -36,384,326	-25%	-$2.86B	2.54%	5
2019 Q1	$11.8B	Sell	146,508,345 -27,059,898	-16%	-$2.21B	3.74%	2
2018 Q4	$16B	Sell	173,568,243 -2,571,964	-1%	-$226M	5.58%	1
2018 Q3	$16.7B	Sell	176,140,207 -17,628,648	-9%	-$1.67B	4.84%	1
2018 Q2	$18B	Buy	193,768,855 +686,114	+0.4%	+$67M	4.9%	1
2018 Q1	$18.3B	Buy	193,082,741 +71,968	+0%	+$7.91M	5.2%	1
2017 Q4	$18.7B	Buy	193,010,773 +3,995,594	+2%	+$377M	5.48%	1
2017 Q3	$16.8B	Buy	189,015,179 +10,740,344	+6%	+$818M	5.07%	1
2017 Q2	$12.9B	Buy	178,274,835 +2,130,919	+1%	+$143M	4.05%	1
2017 Q1	$11.5B	Buy	176,143,916 +1,180,164	+0.7%	+$74.2M	3.62%	1
2016 Q4	$11B	Buy	174,963,752 +13,688,625	+8%	+$836M	3.55%	1
2016 Q3	$10.2B	Buy	161,275,127 +8,556,414	+6%	+$554M	3.36%	2
2016 Q2	$9.44B	Buy	152,718,713 +76,593,054	+101%	+$4.67B	3.23%	2
2016 Q1	$4.35B	Sell	76,125,659 -1,443,000	-2%	-$80.4M	1.5%	11
2015 Q4	$4.6B	Buy	77,568,659 +2,635,205	+4%	+$152M	1.57%	11
2015 Q3	$4.08B	Sell	74,933,454 -8,035,764	-10%	-$523M	1.46%	11
2015 Q2	$5.57B	Sell	82,969,218 -7,484,916	-8%	-$489M	1.83%	8
2015 Q1	$5.3B	Sell	90,454,134 -10,098,455	-10%	-$610M	1.81%	9
2014 Q4	$6.58B	Sell	100,552,589 -12,029,000	-11%	-$758M	2.23%	7
2014 Q3	$6.5B	Buy	112,581,589 +9,693,000	+9%	+$538M	2.25%	6
2014 Q2	$5.81B	Buy	102,888,589 +965,200	+0.9%	+$50.6M	2.03%	8
2014 Q1	$5.24B	Buy	101,923,389 +1,961,264	+2%	+$99.1M	1.89%	9
2013 Q4	$5.28B	Sell	99,962,125 -4,818,713	-5%	-$237M	1.95%	8
2013 Q3	$4.69B	Sell	104,780,838 -2,830,000	-3%	-$125M	1.85%	9
2013 Q2	$4.45B	Buy	+107,610,838	New	+$4.71B	1.89%	8

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Research Global Investors's ABBV Position: Q1 2026 in Review

Capital Research Global Investors increased its AbbVie (ABBV) stake by 23% in Q1 2026, buying an estimated $1.3B and bringing the position to 31,254,786 shares worth $6.8B. The position accounts for 1.05% of the portfolio, ranked #22.

Capital Research Global Investors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.7B in Q4 2017. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Capital Research Global Investors held 31,254,786 shares of AbbVie worth $6.8B as of Q1 2026.
Capital Research Global Investors bought 5,846,586 AbbVie shares in Q1 2026, an estimated $1.3B.
AbbVie made up 1.05% of Capital Research Global Investors's portfolio in Q1 2026, its #22 holding.
Capital Research Global Investors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Capital Research Global Investors's AbbVie position peaked at $18.7B in Q4 2017.
4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.